Sign up Australia
Proactive Investors - Run By Investors For Investors

Amryt Pharma making major advances after successful Lojuxta trial

Dr Helen Phillips, head of medical affairs at Amryt Pharma PLC (LON:AMYT) discusses with Proactive a recently published long-term study of the drug Lojuxta which further confirmed its efficacy in lowering high cholesterol levels resulting from a rare genetic disorder.

The assessment of Lojuxta, also known as lomitapide, followed the progress of patients with Homozygous Familial Hypercholesterolaemia (HoFH).

 
Meet Great Boulder Resources Ltd, Mainstream Group Holdings Ltd, Blackstone Minerals Ltd, Pacific American Coal Ltd and Reward Minerals Ltd at our event, Sydney , 19 November 2018. Register here »
View full AMYT profile View Profile

Amryt Pharma PLC Timeline

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use